Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma

Journal of Viral Hepatitis

Volumn 23, Issue 9, 2016, Pages 718-729

  Lu, Mei ^a   Li, Jia ^a   Rupp, Loralee B ^a   Holmberg, Scott D ^b   Moorman, Anne C ^b   Spradling, Philip R ^b   Teshale, Eyasu H ^b   Zhou, Yueren ^a   Boscarino, Joseph A ^c   Schmidt, Mark A ^d   Lamerato, Lois E ^a   Trinacty, Connie ^e   Trudeau, Sheri ^a   Gordon, Stuart C ^a   Xing, Jim ^f   Tong, Cindy ^f   Nerenz, David R ^f   Akkerman, Nonna ^f   Oja Tebbe, Nancy ^f   Zhang, Talan ^f   Daar, Zahra S ^f   Smith, Robert E ^f   Parker, John V ^f   Donald, Judy L ^f   Keast, Erin M ^f   more..

^a HENRY FORD HEALTH SYSTEM   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c GEISINGER HEALTH SYSTEM   (United States)

^d CENTER FOR HEALTH RESEARCH   (United States)

^e KAISER PERMANENTE   (United States)

^f NONE

Author keywords

antiviral treatment; sustained virological response; treatment failure

Indexed keywords

INTERFERON;

ADULT; AFRICAN AMERICAN; ANTIVIRAL THERAPY; ARTICLE; CANCER RISK; CAUCASIAN; CAUSE OF DEATH; CHRONIC HEPATITIS C; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; FOLLOW UP; HEALTH CARE SYSTEM; HUMAN; LIMIT OF QUANTITATION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT FAILURE;

EID: 84980329350     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12538     Document Type: Article

References (33)

1. Yau AH, Yoshida EM. Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. Can J Gastroenterol Hepatol 2014; 28(8): 445–451.
2. Aleman S, Rahbin N, Weiland O et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013; 57(2): 230–236.
3. Di Bisceglie AM, Shiffman ML, Everson GT et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359(23): 2429–2441.
4. Imai Y, Kawata S, Tamura S et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998; 129(2): 94–99.
5. Shindo M, Ken A, Okuno T. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Cancer 1999; 85(9): 1943–1950.
6. Shiratori Y, Ito Y, Yokosuka O et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142(2): 105–114.
7. Yoshida H, Tateishi R, Arakawa Y et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53(3): 425–430.
8. American Association for the Study of Liver Diseases IDSoA. Recommendations for Testing, Managing, and Treating Hepatitis C. Vol. 2015, 2014.
9. Moorman AC, Gordon SC, Rupp LB et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. Clin Infect Dis 2013; 56(1): 40–50.
10. Li J, Gordon SC, Rupp LB et al. The validity of serum markers for fibrosis staging in chronic hepatitis B and C. J Viral Hepatitis 2014; 21(12): 930–937.
11. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45(6): 613–619.
12. Austin PC. The performance of different propensity-score methods for estimating relative risks. J Clin Epidemiol 2008; 61(6): 537–545.
13. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11(5): 550–560.
14. Steiner JF, Paolino AR, Thompson EE, Larson E. Sustaining research networks: the Twenty-Year Experience of the HMO research network. eGEMS 2014; 2(2): 1067. PMID:254848605.
15. Mahajan R, Xing J, Liu SJ et al. Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006–2010. Clin Infect Dis 2014; 58(8): 1055–1061.
16. SAS Institute Inc. Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference Cary, NC: SAS Institute Inc. 2001.
17. Steventon A, Grieve R, Sekhon J. A comparison of alternative strategies for choosing control populations in observational studies. Health Serv Outcomes Res Method 2015; 15(3): 157–181.
18. Rubin DB. Inference and missing data. Biometrika 1976; 63: 581–592.
19. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med 1991; 10(4): 585–598.
20. Wen Y, Zheng YX, de Tan M. A comprehensive long-term prognosis of chronic hepatitis C patients with antiviral therapy: a meta-analysis of studies from 2008 to 2014. Hepat Mon 2015; 15(5): e27181.
21. Baran B, Gulluoglu M, Soyer OM et al. Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C. J Viral Hepatitis 2014; 21(2): 111–120.
22. Abdelrahman T, Hughes J, Main J, McLauchlan J, Thursz M, Thomson E. Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment. Hepatology (Baltimore, MD) 2015; 61(1): 88–97.
23. El-Serag HB, Kramer J, Duan Z, Kanwal F. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol 2014; 109(9): 1427–1435.
24. Hassan MM, Curley SA, Li D et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010; 116(8): 1938–1946.
25. van der Meer AJ, Veldt BJ, Feld JJ et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308(24): 2584–2593.
26. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 2014; 60(1): 98–105.
27. Messina JP, Humphreys I, Flaxman A et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology (Baltimore, MD) 2015; 61(1): 77–87.
28. Aghemo A, Colombo M. Hepatitis C genotype 3: a tough match for interferon-free regimens. Gastroenterology 2014; 146(4): 1125–1127.
29. Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368(20): 1867–1877.
30. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368(20): 1878–1887.
31. Pierangeli A, Antonelli G, Gentile G. Immunodeficiency-associated viral oncogenesis. Clin Microbiol Infect 2015; 21(11): 975–983.
32. Stuart EA, DuGoff E, Abrams M, et al. Estimating causal effects in observational studies using electronic health data: challenges and (some) solutions. eGEMS 2013; 1(3): 4.
33. Vandenbroucke JP, von Elm E, Altman DG et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg 2014; 12(12): 1500–1524.